Form 4 for CNSP CNS Pharmaceuticals, Inc.

Accepted 2023-05-01 00:00:00 ET · period of report 2023-04-28 · accession 0001683168-23-002830 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-05-01	2023-04-28	CNSP	Climaco John M	CEO, Dir	M - OptEx	—	+1,250	46.3K	+3%	—
D	2023-05-01	2023-04-28	CNSP	Climaco John M	CEO, Dir	M - OptEx	—	-1,250	60.2K	-2%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-04-28	M	A	1,250	—	46,260	D	—	—	(F1) Restricted stock units convert into common stock on a one-for-one basis.
2	Derivative	Restricted Stock Units	2023-04-28	M	D	1,250	—	60,201	D	— · — to —	1,250 Common Stock	(F2) On April 28, 2022, the reporting person received 20,000 restricted stock units vesting as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors. (F1) Restricted stock units convert into common stock on a one-for-one basis.